特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
961503

マイクロバイオームの世界市場 - 考察と予測、COVID-19の潜在的影響:2020年~2024年

Global Microbiomes Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 77 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
マイクロバイオームの世界市場 - 考察と予測、COVID-19の潜在的影響:2020年~2024年
出版日: 2020年09月21日
発行: Koncept Analytics
ページ情報: 英文 77 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のマイクロバイオーム市場は、2024年に93億7600万米ドルに達し、2018年~2024年のCAGRで135.47%の成長が予測されています。高齢者人口の増加、個人の医療費の増加、慢性疾患の発生率の増加、個人の可処分所得の加速、消費者マインドの向上などの要因が、市場を牽引すると予想されています。

当レポートでは、世界のマイクロバイオーム市場について調査分析し、市場規模、市場力学、競合情勢、主要企業など、体系的な情報を提供しています。

目次

第1章 市場概要

  • イントロダクション
  • マイクロバイオーム関連の疾患
  • 今後のマイクロバイオームベース製品

第2章 COVID-19の影響

  • イントロダクション
  • 世界のGDP成長率の低下
  • オーガニックトラフィックの変化
  • 医療費の伸び

第3章 世界のマイクロバイオーム市場分析

  • 世界のマイクロバイオーム市場金額
  • 世界のマイクロバイオーム市場金額:適応別
    • 世界のマイクロバイオーム医薬品市場金額
    • 世界のマイクロバイオーム医薬品市場金額:治療分野別
    • 世界の胃腸病マイクロバイオーム医薬品市場金額
    • 世界の感染症マイクロバイオーム医薬品市場金額
    • 世界の代謝異常マイクロバイオーム医薬品市場金額
    • 世界の腫瘍マイクロバイオーム医薬品市場金額
    • 世界の免疫疾患マイクロバイオーム医薬品市場金額
    • 世界のマイクロバイオーム医薬品市場金額:技術別
    • 世界のマイクロバイオーム診断市場金額
  • 世界のマイクロバイオーム市場金額:製品別
    • 世界のプロバイオティクスマイクロバイオーム市場金額
    • 世界のプレバイオティクスマイクロバイオーム市場金額
  • 世界のマイクロバイオーム市場金額:地域別

第4章 地域のマイクロバイオーム市場分析

  • 北米のマイクロバイオーム市場金額
  • 欧州のマイクロバイオーム市場金額
  • アジア太平洋のマイクロバイオーム市場金額

第5章 市場力学

  • 成長促進要因
  • 主な動向と開発
  • 課題

第6章 競合情勢

  • 世界のマイクロバイオーム市場
    • 主要企業:時価総額の比較
    • 主要企業:研究開発費の比較
    • 主要企業:製品比較

第7章 企業プロファイル

  • Seres Therapeutics, Inc.
  • Synthetic Biologics, Inc.
  • Evelo Biosciences, Inc.
  • 4D Pharma Plc
  • Infant Bacterial Therapeutics AB
  • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Global GDP Growth Rate (2005-2020)
  • Organic Traffic Growth or Decline due to COVID-19 (2020)
  • The U.S. Government Share of Healthcare Spending (2020-2027)
  • Global Microbiomes Market Value (2018-2024)
  • Global Microbiomes Market Value by Applications (2019)
  • Global Microbiomes Drugs Market Value (2018-2024)
  • Global Microbiomes Drugs Market Value by Therapeutic Area (2019)
  • Global Gastroenterology Microbiomes Drugs Market Value (2018-2024)
  • Global Infectious Disease Microbiomes Drugs Market Value (2018-2024)
  • Global Metabolic Disease Microbiomes Drugs Market Value (2018-2024)
  • Global Oncology Microbiomes Drugs Market Value (2018-2024)
  • Global Immunology Microbiomes Drugs Market Value (2018-2024)
  • Global Microbiomes Drugs Market Value by Technology (2019)
  • Global Microbiomes Diagnostics Market Value (2018-2024)
  • Global Microbiomes Market Value by Products (2019)
  • Global Probiotics Microbiomes Market Value (2018-2024)
  • Global Prebiotics Microbiomes Market Value (2018-2024)
  • Global Microbiomes Market Value by Region (2019)
  • North America Microbiomes Market Value (2018-2024)
  • Europe Microbiomes Market Value (2018-2024)
  • Asia-Pacific Microbiomes Market Value (2018-2024)
  • Global Geriatric Population (2015-2019)
  • Global Healthcare Expenditure per Capita (2015-2019)
  • Global Chronic Diseases Growth (2019)
  • Global Gross National Income (GNI) per Capita (2015-2019)
  • Consumer Confidence Index in US and Europe (2015-2019)
  • Global Microbiome Research and Development Activities (2015-2019)
  • Key Players - Research and Development Expenditures Comparison (2018/2019)
  • Seres Therapeutics Revenues and Net Loss (2015-2019)
  • Synthetic Biologics Net Loss (2015-2019)
  • Evelo Biosciences Net Loss (2016-2019)
  • 4D Pharma Revenues and Net Loss (2015-2019)
  • IBT Net Loss (2015-2019)
  • Takeda Revenues and Net Profit (2016-2020)

List of Tables

  • Association of the Gut Microbiome with Therapeutic Effects of Drugs
  • Global Microbiome-based Product Pipelines
  • Global Microbiome Licensing Deals (2015-2018)
  • Key Players - Market Cap Comparison (2020)
  • Key Players - Product Comparison (2020)
  • Evelo Biosciences Product Pipeline
  • 4D Pharma Product Pipeline
目次

The global microbiomes market is forecasted to reach US$9,376 million in 2024, growing at a CAGR of 135.47% for the period spanning 2018-2024. The factors such as growing geriatric population, rising personal healthcare expenditures, increasing chronic diseases incidence, accelerating personal disposable income and improving consumer confidence index are expected to drive the market. However, growth of the industry would be challenged by intellectual property issues, stringent regulatory framework and manufacturing and technology considerations. Few notable trends include progressing product pipeline, increasing product licensing contracts and inclining microbiome research and development activities. In 2020, the outbreak of COVID-19 pandemic has created a favorable impact on the market as the microbiomes-based products sales increased.

The global microbiomes market can be split on the basis of applications into drugs and diagnostics. Currently, drugs occupies the higher share owing to growth in acceptance of probiotics among population and rising prevalence of autoimmune diseases, cancer and gastrointestinal diseases.

The fastest growing regional market is North America owing to rising incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in human microbiome along with next-generation sequencing.

Scope of the report:

  • The report provides a comprehensive analysis of the global microbiomes market, segmented into drugs and diagnostics.
  • The major regional markets (North America, Europe and Asia-Pacific) have been analysed.
  • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Seres Therapeutics, Inc., Synthetic Biologics, Inc., Evelo Biosciences, Inc., 4D Pharma Plc, Infant Bacterial Therapeutics AB and Takeda Pharmaceutical Company Limited) are also presented in detail.

Key Target Audience:

  • Microbiome-based Manufacturers
  • End Users
  • Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Introduction
  • 1.2 Associated Microbiomes Disorders
  • 1.3 Upcoming Microbiomes-based Products

2. Impact of COVID-19

  • 2.1 Introduction
  • 2.2 Decline in Global GDP Growth
  • 2.3 Change in Organic Traffic
  • 2.4 Growth in Spending on Healthcare

3. Global Microbiomes Market Analysis

  • 3.1 Global Microbiomes Market Value
  • 3.2 Global Microbiomes Market Value by Applications
    • 3.2.1 Global Microbiomes Drugs Market Value
    • 3.2.2 Global Microbiomes Drugs Market Value by Therapeutic Area
    • 3.2.3 Global Gastroenterology Microbiomes Drugs Market Value
    • 3.2.4 Global Infectious Disease Microbiomes Drugs Market Value
    • 3.2.5 Global Metabolic Disease Microbiomes Drugs Market Value
    • 3.2.6 Global Oncology Microbiomes Drugs Market Value
    • 3.2.7 Global Immunology Microbiomes Drugs Market Value
    • 3.2.8 Global Microbiomes Drugs Market Value by Technology
    • 3.2.9 Global Microbiomes Diagnostics Market Value
  • 3.3 Global Microbiomes Market Value by Products
    • 3.3.1 Global Probiotics Microbiomes Market Value
    • 3.3.2 Global Prebiotics Microbiomes Market Value
  • 3.4 Global Microbiomes Market Value by Region

4. Regional Microbiomes Market Analysis

  • 4.1 North America Microbiomes Market Value
  • 4.2 Europe Microbiomes Market Value
  • 4.3 Asia-Pacific Microbiomes Market Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Growing Geriatric Population
    • 5.1.2 Rising Personal HealthCare Expenditures
    • 5.1.3 Increasing Chronic Diseases Incidence
    • 5.1.4 Accelerating Personal Disposable Income
    • 5.1.5 Improving Consumer Confidence Index
  • 5.2 Key Trends and Developments
    • 5.2.1 Progressing Product Pipeline
    • 5.2.2 Increasing Product Licensing Contracts
    • 5.2.3 Inclining Microbiome Research and Development Activities
  • 5.3 Challenges
    • 5.3.1 Intellectual Property Issues
    • 5.3.2 Stringent Regulatory Framework
    • 5.3.3 Manufacturing and Technology Considerations

6. Competitive Landscape

  • 6.1 Global Microbiomes Market
    • 6.1.1 Key Players - Market Cap Comparison
    • 6.1.2 Key Players - Research and Development Expenditures Comparison
    • 6.1.3 Key Players - Product Comparison

7. Company Profiles

  • 7.1 Seres Therapeutics, Inc.
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Synthetic Biologics, Inc.
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Evelo Biosciences, Inc.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 4D Pharma Plc
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Infant Bacterial Therapeutics AB
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Takeda Pharmaceutical Company Limited
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.